Anavex Life Sciences (AVXL) Net Income towards Common Stockholders Growth (1y) (2017 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -58.11% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -95.76% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -290.15% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 59.59% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -129.68% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -10.08% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1,228.66% |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | 58.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 58.20% |
| Sep 30, 2025 | 7.66% |
| Jun 30, 2025 | -18.38% |
| Mar 31, 2025 | -18.65% |
| Dec 31, 2024 | -57.64% |
| Sep 30, 2024 | -15.75% |
| Jun 30, 2024 | -8.28% |
| Mar 31, 2024 | 19.54% |
| Dec 31, 2023 | 33.53% |
| Sep 30, 2023 | 29.00% |
| Jun 30, 2023 | 8.79% |
| Mar 31, 2023 | -25.57% |
| Dec 31, 2022 | -19.20% |
| Sep 30, 2022 | -21.95% |
| Jun 30, 2022 | -21.48% |
| Mar 31, 2022 | -27.99% |
| Dec 31, 2021 | -38.54% |
| Sep 30, 2021 | -96.45% |
| Jun 30, 2021 | -56.94% |
| Mar 31, 2021 | -12.69% |
| Dec 31, 2020 | -19.16% |
| Sep 30, 2020 | -6.40% |
| Jun 30, 2020 | 0.54% |
| Mar 31, 2020 | 0.14% |
| Dec 31, 2019 | 4.74% |
| Sep 30, 2019 | -0.25% |
| Jun 30, 2019 | -128.91% |
| Mar 31, 2019 | -52.50% |
| Dec 31, 2018 | -70.47% |
| Sep 30, 2018 | -8.49% |
| Jun 30, 2018 | 21.08% |
| Mar 31, 2018 | -206.76% |
| Dec 31, 2017 | -29.00% |
| Sep 30, 2017 | 20.83% |
| Jun 30, 2017 | -61.14% |